Evotec spin-off company Topas Therapeutics GmbH („Topas“), a private biotechnology company developing immune tolerance-inducing drugs to treat and potentially cure a variety of autoimmune diseases, today announced that the Company has successfully extended its Series B round with an additional € 18 m (~$ 22 m) raised, bringing the total for this financing to € 40 m. All of Topas’ existing investors participated in the extension. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-spin-off-topas-therapeutics-extends-series-b-raising-total-of-eur-40-m–48-m-in-this-round-6078